Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831916 · ClinicalTrials.gov registry record · Phase 2
Impact of Cannabinoids on Menopause Symptoms
A Phase 2 study of Menopause and Perimenopause, sponsored by Washington State University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06831916 is a Phase 2 study of Menopause and Perimenopause that is actively recruiting participants, run by Washington State University. The registered enrollment target is 100 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06831916, a Phase 2 study of Menopause and Perimenopause, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Active Cannabinoid Product
Study Locations (1)
Washington
- Washington State University - Pullman Campus - Pullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831916
The ClinicalTrials.gov registry entry for NCT06831916 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06831916 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06831916 about?
NCT06831916 is a clinical study titled "Impact of Cannabinoids on Menopause Symptoms". The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
What is the current status of trial NCT06831916?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-03-03. Estimated completion is 2027-01-12.
What conditions does trial NCT06831916 study?
This clinical trial studies the following conditions: Menopause, Perimenopause.
What interventions are being tested in trial NCT06831916?
The interventions under investigation include: Placebo (OTHER), Active Cannabinoid Product (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06831916?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831916 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
-
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.